Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: Analytical techniques and challenges

Journal of Pharmaceutical and Biomedical Analysis

Volumn 87, Issue , 2014, Pages 176-190

  Patel, Dhavalkumar Narendrabhai ^a   Li, Lin ^b   Kee, Chee Leong ^c   Ge, Xiaowei ^c   Low, Min Yong ^c   Koh, Hwee Ling ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b CHINESE ACADEMY OF SCIENCES   (China)

^c HEALTH SCIENCES AUTHORITY   (Singapore)

Author keywords

Analytical techniques; Challenges; Designer analogues; PDE 5 inhibitors; Screening for adulterants

Indexed keywords

ACETILDENAFIL; AILDENAFIL; AMINOTADALAFIL; AVANAFIL; BENZYLSILDENAFIL; CARBODENAFIL; DESMETHYLHONGDENAFIL; DIMETHYL SILDENAFIL THIONE; HOMOSILDENAFIL; HONGDENAFIL; HYDROXYACETILDENAFIL; HYDROXYHOMOSILDENAFIL; LODENAFIL; METHISOSILDENAFIL; NOR ACETILDENAFIL; NORNEOSILDENAFIL; PHOSPHODIESTERASE V INHIBITOR; PIPERIDENAFIL; PIPERIDINO ACETILDENAFIL; PIPERIDINO HONGDENAFIL; PIPERIDINO SILDENAFIL; PIPERIDINOVARDENAFIL; SILDENAFIL; SULFODIMETHYL SILDENAFIL; TADALAFIL; THIO METHISOSILDENAFIL; THIOAILDENAFIL; UDENAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL;

ANALYTIC METHOD; CONTROLLED STUDY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOASSAY; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; ION MOBILITY SPECTROSCOPY; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; REVIEW; SPECTROMETRY; SPECTROSCOPY; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY; VIBRATIONAL SPECTROSCOPY; X RAY DIFFRACTION SPECTROMETRY;

(1)H NMR; (13)C NMR; 1 DIMENSIONAL NUCLEAR MAGNETIC RESONANCE; 1D NMR; 2 DIMENSIONAL NUCLEAR MAGNETIC RESONANCE; 2D NMR; ANALYTICAL TECHNIQUES; CAPILLARY ELECTROPHORESIS-MASS SPECTROMETRY; CARBON-13-NUCLEAR MAGNETIC RESONANCE; CART; CE-MS; CHALLENGES; CID; CLASSIFICATION AND REGRESSION TREES; CNLS; COLLISION INDUCED DISSOCIATION; CONSTANT NEUTRAL LOSS SCAN; CORRELATION SPECTROSCOPY; COSY; D-PLS; DAD; DCBI; DEPT; DESIGNER ANALOGUES; DESORPTION CORONA BEAM IONIZATION; DIFFUSION ORDERED SPECTROSCOPY-NUCLEAR MAGNETIC RESONANCE; DIODE ARRAY DETECTOR; DISCRIMINANT PARTIAL LEAST SQUARES; DISTORTIONLESS ENHANCEMENT BY POLARIZATION TRANSFER; DOSY-NMR; ED; ELECTROSPRAY IONIZATION; ERECTILE DYSFUNCTION; ESI; EU; EUROPEAN UNION; FOURIER TRANSFORM ION CYCLOTRON RESONANCE-MASS SPECTROMETRY; FOURIER TRANSFORMED INFRARED; FOURIER TRANSFORMED INFRARED ATTENUATED TOTAL REFLECTANCE; FT-ICR-MS; FT-IR; FTIR-ATR; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GC-MS; HEALTH SCIENCES AUTHORITY SINGAPORE; HETERONUCLEAR MULTIPLE-BOND CORRELATION SPECTROSCOPY; HETERONUCLEAR MULTIPLE-QUANTUM CORRELATION SPECTROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-DESORPTION CORONA BEAM IONIZATION-TANDEM MASS SPECTROMETRY; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HIGH RESOLUTION MASS SPECTROMETRY; HMBC; HMQC; HPLC; HPLC-DCBI-MS/MS; HPTLC; HRMS; HSA; IDA; IMS; INFORMATION DEPENDENT ACQUISITION; ION MOBILITY SPECTROSCOPY; LC-ESI-MS(N); LC-FT-ICR-MS; LC-LTQ ORBITRAP XL FTMS; LC-MS; LC-Q-TOF-MS/MS; LC-TIS-MS; LC-TOF-MS; LIQUID CHROMATOGRAPHY MASS-SPECTROMETRY; LIQUID CHROMATOGRAPHY-ELECTROSPRAY IONIZATION-TANDEM MASS SPECTROMETER; LIQUID CHROMATOGRAPHY-FOURIER TRANSFORM ION CYCLOTRON RESONANCE-MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY-LINEAR ION ORBITRAP XL FOURIER TRANSFORM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY-QUADRUPOLE-TIME-OF-FLIGHT-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY-TIME OF FLIGHT-MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY-TURBO ION SPRAY MASS SPECTROMETRY; MASS SPECTROMETRY; MDMA; METHYLENEDIOXYMETHAMPHETAMINE; MRM; MS; MS(N); MS/MS; MULTI-STAGE MASS SPECTROMETRY; MULTIPLE REACTION MONITORING; NDA; NEAR INFRARED; NEW DRUG APPLICATION; NIR; NMR; NOE; NOESY; NUCLEAR MAGNETIC RESONANCE; NUCLEAR OVERHAUSER EFFECT; NUCLEAR OVERHAUSER EFFECT SPECTROSCOPY; PCA; PDE-5; PDE-5 INHIBITORS; PHOSPHODIESTERASE TYPE 5 ENZYME; PIS; PP; PREC; PRECURSOR ION SCANNING; PRINCIPAL COMPONENT ANALYSIS; PRODUCT ION SCANNING; PROJECTION PURSUIT; PROTON NUCLEAR MAGNETIC RESONANCE; SCREENING FOR ADULTERANTS; SELECTED ION MONITORING; SELECTED REACTION MONITORING; SIM; SIMCA; SOFT INDEPENDENT MODELLING BY CLASS ANALOGY; SRM; SUPPORT VECTOR MACHINES; SVM; TANDEM MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY; THMPD; TIME OF FLIGHT; TIS; TLC; TOF; TQ-LIT; TRADITIONAL HERBAL MEDICINAL PRODUCTS DIRECTIVE; TRIPLE QUADRUPLE LINEAR ION TRAP; TURBO ION SPRAY; UHPLC; ULTRA HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET; UNITED STATES FOOD AND DRUG ADMINISTRATION; USFDA; UV; X-RAY DIFFRACTION; X-RAY FLUORESCENCE; XRD; XRF;

CARBOLINES; CHEMISTRY TECHNIQUES, ANALYTICAL; DRUG CONTAMINATION; HUMANS; IMIDAZOLES; PHARMACEUTICAL PREPARATIONS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PLANT PREPARATIONS; PURINES; SULFONES; TRIAZINES;

EID: 84889577311     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.04.037     Document Type: Review

References (117)

1. FDA approves Stendra for erectile dysfunction, (accessed 01.01.13). http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302140.htm.
2. Shaeer O. The Global Online Sexuality Survey (GOSS): The United States of America in 2011 Chapter II: phosphodiesterase inhibitors utilization among English speakers. J. Sex. Med. 2012, 10:532-540.
3. Shindel A.W. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. J. Sex. Med. 2009, 6:2352-2364.
4. Gur S., Kadowitz P.J., Gokce A., Sikka S.C., Lokman U., Hellstrom W.J. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension. Curr. Drug Metab. 2013, 14:265-269.
5. Venhuis B.J., Kaste D. Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements: a history, analytical aspects and health risks. J. Pharm. Biomed. Anal. 2012, 69:196-208.
6. Low M.Y., Zeng Y., Li L., Ge X.W., Lee R., Bloodworth B.C., Koh H.L. Safety and quality assessment of 175 illegal sexual enhancement products seized in redlight districts in Singapore. Drug Saf. 2009, 32:1141-1146.
7. Venhuis B.J., Zwaagstra M.E., Berg J.D.J.v.d., Riel A.J.H.P.v., Wagenaar H.W.G., Grootheest K.v., Barends D., Kaste D.d. Illicit Erectile Dysfunction Products in the Netherlands; A Decade of Trends and A 2007-2010 Product Update, RIVM Rapport 370030003 2010, 75. National Institute for Public Health and the Environment.
8. Sugita M., Miyakawa M. Economic analysis of use of counterfeit drugs: health impairment risk of counterfeit phosphodiesterase type 5 inhibitor taken as an example. Environ. Health Preventive Med. 2010, 15:244-251.
9. Singh S., Prasad B., Savaliya A.A., Shah R.P., Gohil V.M., Kaur A. Strategies for characterizing sildenafil, vardenafil, tadalafil and their analogues in herbal dietary supplements, and detecting counterfeit products containing these drugs. Trends Anal. Chem. 2009, 28:13-28.
10. Schnetzler G., Banks I., Kirby M., Zou K.H., Symonds T. Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors. J. Sex. Med. 2010, 7:1237-1246.
11. Patel D.N., Low W.L., Tan L.L., Tan M.M., Zhang Q., Low M.Y., Chan C.L., Koh H.L. Adverse events associated with the use of complementary medicine and health supplements: an analysis of reports in the Singapore Pharmacovigilance database from 1998 to 2009. Clin. Toxicol. (Phila.) 2012, 50:481-489.
12. Poon W.T., Lam Y.H., Lai C.K., Chan A.Y., Mak T.W. Analogues of erectile dysfunction drugs: an under-recognised threat. Hong Kong Med. J. 2007, 13:359-363.
13. Alp M., Coşkun M., Göker H. Isolation and identification of a new sildenafil analogue adulterated in energy drink: propoxyphenyl sildenafil. J. Pharm. Biomed. Anal. 2013, 72:155-158.
14. Li L., Low M.Y., Ge X., Bloodworth B.C., Koh H.L. Isolation and structural elucidation of a new sildenafil analogue from a functional coffee. Anal. Bioanal. Chem. 2012, (July).
15. Shin M.H., Hong M.K., Kim W.S., Lee Y.J., Jeoung Y.C. Identification of a new analogue of sildenafil added illegally to a functional food marketed for penile erectile dysfunction. Food Addit. Contam. 2003, 20:793-796.
16. Japanese Food and Drug Administration Ministry, Concerning the discovery of a so-called health food (unlicensed and non-permitted) containing a sildenafil-like substance (hydroxy-homosildenafil), 2004, (accessed 01.02.13). http://www.mhlw.go.jp/houdou/2004/02/h0213-3.html.
17. Blok-Tip L., Zomer B., Bakker F., Hartog K.D., Hamzink M., Ten Hove J., Vredenbregt M., De Kaste D. Structure elucidation of sildenafil analogues in herbal products. Food Addit. Contam. 2004, 21:737-748.
18. Zou P., Hou P., Low M.-Y., Koh H.L. Structural elucidation of a tadalafil analogue found as an adulterant of a herbal product. Food Addit. Contam. 2006, 23:446-451.
19. Zou P., Hou P., Oh S.S., Low M.Y., Koh H.L. Electrospray tandem mass spectrometric investigations of tadalafil and its analogue. Rapid Commun. Mass Spectrom. 2006, 20:3488-3490.
20. Hou P., Zou P., Low M.Y., Chan E., Koh H.L. Structural identification of a new acetildenafil analogue from pre-mixed bulk powder intended as a dietary supplement. Food Addit. Contam. 2006, 23:870-875.
21. Reepmeyer J.C., Woodruff J.T. Use of liquid chromatography-mass spectrometry and a hydrolytic technique for the detection and structure elucidation of a novel synthetic vardenafil designer drug added illegally to a natural herbal dietary supplement. J. Chromatogr. A 2006, 1125:67-75.
22. Gratz S.R., Gamble B.M., Flurer R.A. Accurate mass measurement using Fourier transform ion cyclotron resonance mass spectrometry for structure elucidation of designer drug analogs of tadalafil, vardenafil and sildenafil in herbal and pharmaceutical matrices. Rapid Commun. Mass Spectrom. 2006, 20:2317-2327.
23. Park H.J., Jeong H.K., Chang M.I., Im M.H., Jeong J.Y., Choi D.M., Park K., Hong M.K., Youm J., Han S.B., Kim D.J., Park J.H., Kwon S.W. Structure determination of new analogues of vardenafil and sildenafil in dietary supplements. Food Addit. Contam. 2007, 24:122-129.
24. Korean National Institute of Food and Drug Safety Evaluation, Instrumental Analysis Data of Illegal Compounds in Food, 2010, (accessed 01.01.13). http://www.nifds.go.kr/.
25. Reepmeyer J.C., Woodruff J.T. Use of liquid chromatography-mass spectrometry and a chemical cleavage reaction for the structure elucidation of a new sildenafil analogue detected as an adulterant in an herbal dietary supplement. J. Pharm. Biomed. Anal. 2007, 44:887-893.
26. Reepmeyer J.C., Woodruff J.T., d'Avignon D.A. Structure elucidation of a novel analogue of sildenafil detected as an adulterant in an herbal dietary supplement. J. Pharm. Biomed. Anal. 2007, 43:1615-1621.
27. Venhuis B.J., Barends D.M., Zwaagstra M.E., de Kaste D. Recent developments in counterfeits and imitations of Viagra, Cialis and Levitra, A 2005-2006 Update 2010, National Institute for Public Health and the Environment, RIVM Report 370030001, 2007.
28. Reepmeyer J.C., d'Avignon D.A. Structure elucidation of thioketone analogues of sildenafil detected as adulterants in herbal aphrodisiacs. J. Pharm. Biomed. Anal. 2009, 49:145-150.
29. Ge X., Low M.Y., Zou P., Lin L., Yin S.O., Bloodworth B.C., Koh H.L. Structural elucidation of a PDE-5 inhibitor detected as an adulterant in a health supplement. J. Pharm. Biomed. Anal. 2008, 48:1070-1075.
30. Uchiyama N., Saisho K., Kikura-Hanajiri R., Haishima Y., Goda Y. Determination of a new type of phosphodiesterase-5 inhibitor, thioquinapiperifil, in a dietary supplement promoted for sexual enhancement. Chem. Pharm. Bull. 2008, 56:1331-1334.
31. Zou P., Hou P., Oh S.S., Bloodworth B.C., Low M.Y., Koh H.L. Isolation and identification of thiohomosildenafil and thiosildenafil in health supplements. J. Pharm. Biomed. Anal. 2008, 47:279-284.
32. Venhuis B.J., Zomer G., de Kaste D. Structure elucidation of a novel synthetic thiono analogue of sildenafil detected in an alleged herbal aphrodisiac. J. Pharm. Biomed. Anal. 2008, 46:814-817.
33. Zou P., Hou P., Oh S.S., Bloodworth B.C., Low M.Y., Koh H.L. Identification of benzamidenafil, a new class of phosphodiesterase-5 inhibitor, as an adulterant in a dietary supplement. J. Pharm. Biomed. Anal. 2008, 47:255-259.
34. Kumasaka K., Kawahara N., Doi K., Kojima T., Goda Y. Determination of (R)-xanthoanthrafil, a phosphodiesterase-5 inhibitor, in a dietary supplement promoted for sexual enhancement. Chem. Pharm. Bull. 2008, 56:227-230.
35. Lam Y.H., Poon W.T., Lai C.K., Chan A.Y., Mak T.W. Identification of a novel vardenafil analogue in herbal product. J. Pharm. Biomed. Anal. 2008, 46:804-807.
36. Hasegawa T., Saijo M., Ishii T., Nagata T., Haishima Y., Kawahara N., Goda Y. Structural elucidation of a tadalafil analogue found in a dietary supplement. Shokuhin Eiseigaku Zasshi 2008, 49:311-315.
37. Lai K.C., Liu Y.C., Liao Y.C., Lin Y.L., Tsai L.Y., Lin J.H., Lo C.F. Isolation and identification of three thio-sildenafil analogues in dietary supplements. J. Food Drug Anal. 2010, 18:269-278.
38. Lin M.C., Liu Y.C., Lin Y.L., Lin J.H. Isolation and identification of a novel sildenafil analogue adulterated in dietary supplements. J. Food Drug Anal. 2008, 16:15-20.
39. Choi D.M., Park S., Yoon T.H., Jeong H.K., Pyo J.S., Park J., Kim D., Kwon S.W. Determination of analogs of sildenafil and vardenafil in foods by column liquid chromatography with a photodiode array detector, mass spectrometry, and nuclear magnetic resonance spectrometry. J. AOAC Int. 2008, 91:580-588.
40. HSA cautions against consuming Menergy M-essence capsules found to contain undeclared ingredients, Health Sciences Authority, Singapore, press release, 12 December, 2008, (accessed 02.02.13). http://www.hsa.gov.sg/publish/hsaportal/en/news_events/press_releases/2008.html.
41. Kurita H., Mizuno K., Kuromi K., Suzuki N., Ueno C., Kamimura M. Identification of aminotadalafil and its stereoisomers contained in health foods using chiral liquid chromatography-mass spectrometry. J. Health Sci. 2008, 54:310-314.
42. Li L., Low M.Y., Aliwarga F., Teo J., Ge X.W., Zeng Y., Bloodworth B.C., Koh H.L. Isolation and identification of hydroxythiohomosildenafil in herbal dietary supplements sold as sexual performance enhancement products. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 2009, 26:145-151.
43. Hasegawa T., Takahashi K., Saijo M., Ishii T., Nagata T., Kurihara M., Haishima Y., Goda Y., Kawahara N. Isolation and structural elucidation of cyclopentynafil and N-octylnortadalafil found in a dietary supplement. Chem. Pharm. Bull. (Tokyo) 2009, 57:185-189.
44. Häberli A., Girard P., Low M.Y., Ge X. Isolation and structure elucidation of an interaction product of aminotadalafil found in an illegal health food product. J. Pharm. Biomed. Anal. 2010, 53:24-28.
45. Göker H., Coş Kun M., Alp M. Isolation and identification of a new acetildenafil analogue used to adulterate a dietary supplement: dimethylacetildenafil. Turkish J. Chem. 2010, 34:157-163.
46. Yuk S. Combating illegal foods and drugs containing unauthorized sub-stances. 4th Seminar of European Customs Chemists 2010.
47. Venhuis B.J., Zomer G., Vredenbregt M.J., de Kaste D. The identification of (-)-trans-tadalafil, tadalafil, and sildenafil in counterfeit Cialis and the optical purity of tadalafil stereoisomers. J. Pharm. Biomed. Anal. 2009, 51:723-727.
48. Ge X., Li L., Koh H.L., Low M.Y. Identification of a new sildenafil analogue in a health supplement. J. Pharm. Biomed. Anal. 2011, 56:491-496.
49. Wollein U., Eisenreich W., Schramek N. Identification of novel sildenafil analogues in an adulterated herbal food supplement. J. Pharm. Biomed. Anal. 2011, 56:705-712.
50. Venhuis B.J., Zomer G., Hamzink M., Meiring H.D., Aubin Y., de Kaste D. The identification of a nitrosated prodrug of the PDE-5 inhibitor aildenafil in a dietary supplement: a Viagra with a pop. J. Pharm. Biomed. Anal. 2011, 54:735-741.
51. Demizu Y., Wakana D., Kamakura H., Kurihara M., Okuda H., Goda Y. Identification of mutaprodenafil in a dietary supplement and its subsequent synthesis. Chem. Pharm. Bull. 2011, 59:1314-1316.
52. Lee H.M., Kim C.S., Jang Y.M., Kwon S.W., Lee B.J. Separation and structural elucidation of a novel analogue of vardenafil included as an adulterant in a dietary supplement by liquid chromatography-electrospray ionization mass spectrometry, infrared spectroscopy and nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 2011, 54:491-496.
53. Toomey V.M., Litzau J.J., Flurer C.L. Isolation and structural characterization of two tadalafil analogs found in dietary supplements. J. Pharm. Biomed. Anal. 2011, 59:50-57.
54. Vaysse J., Gilard V., Balayssac S., Zedde C., Martino R., Malet-Martino M. Identification of a novel sildenafil analogue in an adulterated herbal supplement. J. Pharm. Biomed. Anal. 2012, 59:58-66.
55. Kee C.L., Ge X., Koh H.L., Low M.Y. Isolation and characterization of propoxyphenyl linked sildenafil and thiosildenafil analogues in health supplements. J. Pharm. Biomed. Anal. 2012, 70:265-272.
56. Balayssac S., Gilard V., Zedde C., Martino R., Malet-Martino M. Analysis of herbal dietary supplements for sexual performance enhancement: first characterization of propoxyphenyl-thiohydroxyhomosildenafil and identification of sildenafil, thiosildenafil, phentolamine and tetrahydropalmatine as adulterants. J. Pharm. Biomed. Anal. 2012, 63:135-150.
57. Lee E.S., Kim J.W., Lee J.H., Han K.M., Cho S., Hwang I.S., Han S.Y., Chae K.R., Kim J. Identification of a new tadalafil analogue found in a dietary supplement. Food Addit. Contam. Part A 2013, (February). (in press).
58. Jankovics P., Lohner S., Darcsi A., Németh-Palotás J., Béni S. Detection and structure elucidation of hydroxythiovardenafil as an adulterant in a herbal dietary supplement. J. Pharm. Biomed. Anal. 2013, 74:83-91.
59. Kee C.L., Ge X., Koh H.L., Low M.Y. Structural elucidation of a new sildenafil analogue using high resolution Orbitrap mass spectrometry. Rapid Commun. Mass Spectrom. 2013, 27:1380-1384.
60. Jung J., Choi S., Cho S.H., Ghim J.L., Hwang A., Kim U., Kim B.S., Koguchi A., Miyoshi S., Okabe H., Bae K.S., Lim H.S. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther. 2010, 32:1178-1187.
61. Toque H., Teixeira C.E., Lorenzetti R., Okuyama C.E., Antunes E., De Nucci G. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE-5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur. J. Pharmacol. 2008, 591:189-195.
62. Gratz S.R., Flurer C.L., Wolnik K.A. Analysis of undeclared synthetic phosphodiesterase-5 inhibitors in dietary supplements and herbal matrices by LC-ESI-MS and LC-UV. J. Pharm. Biomed. Anal. 2004, 36:525-533.
63. Lai K.C., Liu Y.C., Tseng M.C., Lin J.H. Isolation and identification of sildenafil analogue illegally added in dietary supplements. J. Food Drug Anal. 2006, 14:19-23.
64. van Deursen M.M., Lock E.R., Poortman-van der Meere A.J. Organic impurity profiling of 3,4-methylenedioxymethamphetamine (MDMA) tablets seized in The Netherlands. Sci. Justice 2006, 46:135-152.
65. J.H. Kim, Y. Kim, K.I. Choi, D.H. Kim, G. Nam, J.H. Seo, Novel pyrazolopyrimidinethione derivatives, preparation methods thereof and their use as therapeutics for erectile dysfunction, US Patent 0176371 A1, 2004.
66. HSA Alerts Public to Adverse Reactions Related to the Consumption of Adulterated Health Products, Including a Fatal Case, Health Sciences Authority, Singapore, press release, 3 October, 2012, (accessed 22.04.13). http://www.hsa.gov.sg/publish/hsaportal/en/news_events/press_releases/2012/hsa_alerts_public0.html.
67. Daugan A., Grondin P., Ruault C., Le Monnier de Gouville A.C., Coste H., Linget J.M., Kirilovsky J., Hyafil F., Labaudiniere R. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues. J. Med. Chem. 2003, 46:4533-4542.
68. Kurita H., Mizuno K., Kuromi K., Suzuki N., Ueno C., Kamimura M., Fujiwara A., Owada K., Ogo N., Yamamoto M. Identification of aminotadalafil and its stereoisomers contained in health foods using chiral liquid chromatography-mass spectrometry. J. Health Sci. 2008, 54:310-314.
69. Cai Y., Cai T.G., Shi Y., Cheng X.L., Ma L.Y., Ma S.C., Lin R.C., Feng W. Simultaneous determination of eight PDE5-IS potentially adulterated in herbal dietary supplements with TLC and HPLC-PDA-MS methods. J. Liquid Chromatogr. Relat. Technol. 2010, 33:1287-1306.
70. Moriyasu T., Shigeoka S., Kishimoto K., Ishikawa F., Nakajima J., Kamimura H., Yasuda I. Identification system for Sildenafil in health foods. Yakugaku Zasshi. 2001, 121:765-769.
71. Mikami E., Ohno T., Matsumoto H. Simultaneous identification/determination system for phentolamine and sildenafil as adulterants in soft drinks advertising roborant nutrition. Forensic Sci Int. 2002, 130:140-146.
72. Abourashed E., Abdel-Kader M.S., Habib A.A.M. HPTLC determination of sildenafil in pharmaceutical products and aphrodisiac herbal preparations. J. Planar Chromatogr. Mod. TLC 2005, 18:372-376.
73. Reddy T.S., Reddy A.S., Devi P.S. Quantitative determination of sildenafil citrate in herbal medicinal formulations by high-performance thin-layer chromatography. J. Planar Chromatogr. Mod. TLC 2006, 19:427-431.
74. Görög S. The paradigm shifting role of chromatographic methods in pharmaceutical analysis. J. Pharm. Biomed. Anal. 2012, 69:2-8.
75. Liu S.Y., Woo S.O., Koh H.L. HPLC and GC-MS screening of Chinese proprietary medicine for undeclared therapeutic substances. J. Pharm. Biomed. Anal. 2001, 24:983-992.
76. Zou P., Oh S.S., Hou P., Low M.Y., Koh H.L. Simultaneous determination of synthetic phosphodiesterase-5 inhibitors found in a dietary supplement and pre-mixed bulk powders for dietary supplements using high-performance liquid chromatography with diode array detection and liquid chromatography-electrospray ionization tandem mass spectrometry. J. Chromatogr. A. 2006, 1104:113-122.
77. Sacré P.Y., Deconinck E., Chiap P., Crommen J., Mansion F., Rozet E., Courselle P., De Beer J.O. Development and validation of an ultra-high-performance liquid chromatography-UV method for the detection and quantification of erectile dysfunction drugs and some of their analogues found in counterfeit medicines. J. Chromatogr. A 2011, 1218:6439-6447.
78. Singh S., Handa T., Narayanam M., Sahu A., Junwal M., Shah R.P. A critical review on the use of modern sophisticated hyphenated tools in the characterization of impurities and degradation products. J. Pharm. Biomed. Anal. 2012, 69:148-173.
79. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
80. Koh H.L., Yau W.P., Ong P.S., Hegde A. Current trends in modern pharmaceutical analysis for drug discovery. Drug Discov. Today 2003, 8:889-897.
81. Petucci C., Diffendal J. Atmospheric solids analysis probe: a rapid ionization technique for small molecule drugs. J. Mass Spectrom. 2008, 43:1565-1568.
82. Twohig M., Skilton S.J., Fujimoto G., Ellor N., Plumb R.S. Rapid detection and identification of counterfeit and [corrected] adulterated products of synthetic phosphodiesterase type-5 inhibitors with an atmospheric solids analysis probe. Drug Test Anal. 2010, 2:45-50. Erratum in: Drug Test Anal. 3 (2011) 191-193.
83. Wang H., Sun W., Zhang J., Yang X., Lin T., Ding L. Desorption corona beam ionization source for mass spectrometry. Analyst 2010, 135:688-695.
84. Li X., Wang H., Sun W., Ding L. Desorption corona beam ionization coupled with a poly(dimethylsiloxane) substrate: broadening the application of ambient ionization for water samples. Anal. Chem. 2010, 82:9188-9193.
85. Wu S., Wang H., Zhu H.G., Zhao Y., Tian Q.Q., Sun W.J., Ding L., Chen B. Rapid determination of illegally added phosphodiesterase 5 inhibitors in health food by desorption corona beam ionization-tandem mass spectrometry. Chin. J. Anal. Chem. 2012, 40:1081-1085.
86. Liu L., Zhou S., Cheng L. Rapid determination of some PDE-5 inhibitors and there analogues in health supplement used for sexual enhancement. Herald Med. 2012, 31:507-509.
87. Lee H.M., Lee B.J. A novel approach to simultaneous screening and confirmation of regulated pharmaceutical compounds in dietary supplements by LC/MS/MS with an information-dependent acquisition method. Food Addit. Contam. Part A Chem. Anal. Control Expo. Risk Assess. 2011, 28:396-407.
88. ®) and its N-desmethyl metabolite in rat and human hair by GC-MS. Biol. Pharm. Bull. 2001, 24:1384-1388.
89. Man C.N., Nor N.M., Lajis R., Harn G.L. Identification of sildenafil, tadalafil and vardenafil by gas chromatography-mass spectrometry on short capillary column. J. Chromatogr. A 2009, 1216:8426-8430.
90. Papoutsis I., Nikolaou P., Athanaselis S., Alevizopoulos G., Pistos C., Paraskevopoulou C., Spiliopoulou C. Development and validation of a gas chromatography-mass spectrometric method for the determination of sildenafil and desmethyl-sildenafil in whole blood. J. Sep. Sci. 2011, 34:3037-3042.
91. Strano-Rossi S., Anzillotti L., de la Torre X., Botrè F. A gas chromatography/mass spectrometry method for the determination of sildenafil, vardenafil and tadalafil and their metabolites in human urine. Rapid Commun. Mass Spectrom. 2010, 24:1697-1706.
92. de Veij M., Deneckere A., Vandenabeele P., de Kaste D., Moens L. Detection of counterfeit Viagra with Raman spectroscopy. J. Pharm. Biomed. Anal. 2008, 46:303-309.
93. Deconinck E., Sacré P.Y., Courselle P., De Beer J.O. Chemometrics and chromatographic fingerprints to discriminate and classify counterfeit medicines containing PDE-5 inhibitors. Talanta 2012, 100:123-133.
94. Deconinck F., Sacré P.Y., Coomans D., De Beer J. Classification trees based on infrared spectroscopic data to discriminate between genuine and counterfeit medicines. J. Pharm. Biomed. Anal. 2012, 57:68-75.
95. 1H NMR and Raman spectroscopy. J. Pharm. Biomed. Anal. 2008, 47:103-113.
96. Trefi S., Gilard V., Balayssac S., Malet-Martino M., Martino R. The usefulness of 2D DOSY and 3D DOSY-COSY 1H NMR for mixture analysis: application to genuine and fake formulations of sildenafil (Viagra). Magn. Reson. Chem. 2009, 47:S163-S173.
97. 1H NMR, a useful tool for analysis of complex mixtures: application to herbal drugs or dietary supplements for erectile dysfunction. J. Pharm. Biomed. Anal. 2009, 50:602-612.
98. Maurin J.K., Pluciński F., Mazurek A.P., Fijałek Z. The usefulness of simple X-ray powder diffraction analysis for counterfeit control-the Viagra example. J. Pharm. Biomed. Anal 2007, 43:1514-1518.
99. Ortiz R.S., Mariotti K.C., Schwab N.V., Sabin G.P., Rocha W.F., de Castro E.V., Limberger R.P., Mayorga P., Bueno M.I., Romão W. Fingerprinting of sildenafil citrate and tadalafil tablets in pharmaceutical formulations via X-ray fluorescence (XRF) spectrometry. J. Pharm. Biomed. Anal. 2012, 58:7-11.
100. Gryniewicz C.M., Reepmeyer J.C., Kauffman J.F., Buhse L.F. Detection of undeclared erectile dysfunction drugs and analogues in dietary supplements by ion mobility spectrometry. J. Pharm. Biomed. Anal 2009, 49:601-606.
101. Mans D.J., Callahan R.J., Dunn J.D., Gryniewicz-Ruzicka C.M. Rapid-screening detection of acetildenafils, sildenafils and avanafil by ion mobility spectrometry. J. Pharm. Biomed. Anal. 2012, 75C:153-157.
102. Perr J.M., Furton K.G., Almirall J.R. Solid phase microextraction ion mobility spectrometer interface for explosive and taggant detection. J. Sep. Sci. 2005, 28:177-183.
103. Strege M.A., Kozerski J., Juarbe N., Mahoney P. At-line quantitative ion mobility spectrometry for direct analysis of swabs for pharmaceutical manufacturing equipment cleaning verification. Anal. Chem. 2008, 80:3040-3044.
104. Guo J.B., Xu Y., Huang Z.B., He Q.H., Liu S.W. Development of an immunoassay for rapid screening of vardenafil and its potential analogues in herbal products based on a group specific monoclonal antibody. Anal. Chim. Acta 2010, 658:197-203.
105. Song Y., Wang Y.Y., Zhang Y., Wang S. Development of enzyme-linked immunosorbent assay for rapid determination of sildenafil in adulterated functional foods. Food Agric. Immunol. 2012, 23:338-351.
106. Reepmeyer J.C., D'Avignon D.A. Use of a hydrolytic procedure and spectrometric methods in the structure elucidation of a thiocarbonyl analogue of sildenafil detected as an adulterant in an over-the-counter herbal aphrodisiac. J AOAC Int. 2009, 92:1336-1342.
107. Low M.Y., Li L., Ge X., Kee C.L., Koh H.L. Isolation and structural elucidation of flibanserin as an adulterant in a health supplement used for female sexual performance enhancement. J. Pharm. Biomed. Anal. 2012, 57:104-108.
108. FDA, Summary Minutes of the Advisory Committee for Reproductive Health Drugs (18.06.10), (accessed 29.04.11). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM248751.pdf.
109. Medsafe, Health products alert INV10019, 2010, (accessed 01.01.13). http://www.medsafe.govt.nz/profs/PUArticles/AdulteratedErectileSept10.htm.
110. Venhuis B.J., Tan J., Vredenbregt M.J., Ge X., Low M.Y., de Kaste D. Capsule shells adulterated with tadalafil. Forensic Sci. Int. 2012, 214:e20-e22.
111. Poon W.T., Lam Y.H., Lee H.H., Ching C.K., Chan W.T., Chan S.S., Lai C.K., Tse M.L., Chan A.Y., Mak T.W. Outbreak of hypoglycaemia: sexual enhancement products containing oral hypoglycaemic agent. Hong Kong Med. J. 2009, 15:196-200.
112. Muller D., Weinmann W., Hermanns-Clausen M. Chinese slimming capsules containing sibutramine sold over the Internet: a case series. Dtsch. Arztebl. Int. 2009, 106:218-222.
113. Fan T.P., Deal G., Koo H.L., Rees D., Sun H., Chen S., Dou J.H., Makarov V.G., Pozharitskaya O.N., Shikov A.N., Kim Y.S., Huang Y.T., Chang Y.S., Jia W., Dias A., Wong V.C., Chan K. Future development of global regulations of Chinese herbal products. J. Ethnopharmacol. 2012, 140:568-586.
114. Gilbert N., Regulations Herbal medicine rule book. Nature 2011, 480:S98-S99.
115. Silano V., Coppens P., Larrañaga-Guetaria A., Minghetti P., Roth-Ehrang R. Regulations applicable to plant food supplements and related products in the European Union. Food Funct. 2011, 2:710-719.
116. Quintus C., Schweim H.G. European regulation of herbal medicinal products on the border area to the food sector. Phytomedicine 2012, 19:378-381.
117. Classification tree for products in the food-health product interface, Health Sciences Authority, Singapore, (accessed 23.04.13). http://www.hsa.gov.sg/publish/etc/medialib/hsa_library/health_products_regulation/complementary_medicines/files_1.Par.31927.File.dat/ClassificationTreeFeb07pdf.pdf.